Understanding the Market | KINTOR PHARMA-B rose over 8% in the morning as the company is actively advancing the registration application preparation for KT-939
I'm PortAI, I can summarize articles.
KINTOR PHARMA-B's stock price rose more than 8% in the morning, reaching HKD 2.42, with a transaction volume of HKD 9.6388 million. The company is actively advancing the registration application for the new efficient tyrosinase inhibitor KT-939, planning to submit the application to the drug regulatory authority in the third quarter of next year. KT-939 has completed multiple safety and toxicology assessments, performing well, and is expected to become the first independently developed and approved new raw material for whitening cosmetic products in China
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments